These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 34319509)
1. Glioblastoma Therapy: Rationale for a Mesenchymal Stem Cell-based Vehicle to Carry Recombinant Viruses. Ali S; Xia Q; Muhammad T; Liu L; Meng X; Bars-Cortina D; Khan AA; Huang Y; Dong L Stem Cell Rev Rep; 2022 Feb; 18(2):523-543. PubMed ID: 34319509 [TBL] [Abstract][Full Text] [Related]
2. Emerging role of oncolytic viruses and stem cells in gene therapy: Should they be integrated? Tahir M; Ahmad N; Lei D; Ali S Drug Discov Today; 2022 Aug; 27(8):2244-2251. PubMed ID: 35351608 [TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stem cells loaded with Ad5-Ki67/IL-15 enhance oncolytic adenovirotherapy in experimental glioblastoma. Wang P; Zhang J; Zhang Q; Liu F Biomed Pharmacother; 2023 Jan; 157():114035. PubMed ID: 36434955 [TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cells used as carrier cells of oncolytic adenovirus results in enhanced oncolytic virotherapy. Mahasa KJ; de Pillis L; Ouifki R; Eladdadi A; Maini P; Yoon AR; Yun CO Sci Rep; 2020 Jan; 10(1):425. PubMed ID: 31949228 [TBL] [Abstract][Full Text] [Related]
5. Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies. Shah S Med Sci (Basel); 2023 Dec; 12(1):. PubMed ID: 38249077 [TBL] [Abstract][Full Text] [Related]
6. Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Parker Kerrigan BC; Shimizu Y; Andreeff M; Lang FF Cytotherapy; 2017 Apr; 19(4):445-457. PubMed ID: 28233640 [TBL] [Abstract][Full Text] [Related]
7. Mesenchymal stem cells loaded with oncolytic reovirus enhances antitumor activity in mice models of colorectal cancer. Babaei A; Soleimanjahi H; Soleimani M; Arefian E Biochem Pharmacol; 2021 Aug; 190():114644. PubMed ID: 34090878 [TBL] [Abstract][Full Text] [Related]
8. Intraarterial delivery of virotherapy for glioblastoma. Srinivasan VM; Lang FF; Kan P Neurosurg Focus; 2021 Feb; 50(2):E7. PubMed ID: 33524944 [TBL] [Abstract][Full Text] [Related]
9. Cancer stem cell plasticity in glioblastoma multiforme: a perspective on future directions in oncolytic virotherapy. Kim DS Future Oncol; 2020 Oct; 16(28):2251-2264. PubMed ID: 32744059 [TBL] [Abstract][Full Text] [Related]
10. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006 [TBL] [Abstract][Full Text] [Related]
12. Directing systemic oncolytic viral delivery to tumors via carrier cells. Nakashima H; Kaur B; Chiocca EA Cytokine Growth Factor Rev; 2010; 21(2-3):119-26. PubMed ID: 20226717 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors. Yoon AR; Rivera-Cruz C; Gimble JM; Yun CO; Figueiredo ML Mol Ther Oncolytics; 2022 Jun; 25():78-97. PubMed ID: 35434272 [TBL] [Abstract][Full Text] [Related]
14. Canine Adipose-Derived Mesenchymal Stem Cells (cAdMSCs) as a "Trojan Horse" in Vaccinia Virus Mediated Oncolytic Therapy against Canine Soft Tissue Sarcomas. Petrov I; Gentschev I; Vyalkova A; Elashry MI; Klymiuk MC; Arnhold S; Szalay AA Viruses; 2020 Jul; 12(7):. PubMed ID: 32664672 [TBL] [Abstract][Full Text] [Related]
15. Recent advances in targeting cancer stem cells using oncolytic viruses. Zhang YN; Wang SB; Song SS; Hu PY; Zhou YC; Mou YP; Mou XZ Biotechnol Lett; 2020 Jun; 42(6):865-874. PubMed ID: 32166558 [TBL] [Abstract][Full Text] [Related]
16. A specific subpopulation of mesenchymal stromal cell carriers overrides melanoma resistance to an oncolytic adenovirus. Bolontrade MF; Sganga L; Piaggio E; Viale DL; Sorrentino MA; Robinson A; Sevlever G; García MG; Mazzolini G; Podhajcer OL Stem Cells Dev; 2012 Sep; 21(14):2689-702. PubMed ID: 22462538 [TBL] [Abstract][Full Text] [Related]
17. Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells. Osali A; Zhiani M; Ghaebi M; Meymanat M; Esmaeilzadeh A Pharmacol Res; 2020 Nov; 161():105094. PubMed ID: 32795509 [TBL] [Abstract][Full Text] [Related]
18. In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. McKenzie BA; Zemp FJ; Pisklakova A; Narendran A; McFadden G; Lun X; Kenchappa RS; Kurz EU; Forsyth PA Neuro Oncol; 2015 Aug; 17(8):1086-94. PubMed ID: 25605818 [TBL] [Abstract][Full Text] [Related]
19. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma. Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209 [TBL] [Abstract][Full Text] [Related]
20. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study. García-Castro J; Alemany R; Cascalló M; Martínez-Quintanilla J; Arriero Mdel M; Lassaletta A; Madero L; Ramírez M Cancer Gene Ther; 2010 Jul; 17(7):476-83. PubMed ID: 20168350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]